ImportRefusal LogoImportRefusal

Intas Pharmaceuticals Limited

⚠️ High Risk

FEI: 3000978756 • Ahmedabad, Gujarat • INDIA

FEI

FEI Number

3000978756

📍

Location

Ahmedabad, Gujarat

🇮🇳

Country

INDIA
🏢

Address

Plot 255, Magnet Corporate Park, Near sola bridge, S.G. Highway, Thaltej, Ahmedabad, Gujarat, India

High Risk

FDA Import Risk Assessment

67.2
LowModerateHighCritical

This firm has a significant history of FDA import refusals with notable violations.

Statistics

26
Total Refusals
4
Unique Violations
3/31/2025
Latest Refusal
2/15/2011
Earliest Refusal

Score Breakdown

Violation Severity
81.5×40%
Refusal Volume
53.0×30%
Recency
84.0×20%
Frequency
18.4×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

7525×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

1184×

NOT LISTED

It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).

32803×

FRNMFGREG

The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.

1861×

INSANITARY

The article is subject to refusal of admission pursuant to section 801(a)(3) in that the article appears to have been prepared, packed, or held under insanitary conditions whereby it may have been contaminated with filth, or whereby it may have been rendered injurious to health.

Refusal History

DateProductViolationsDivision
3/31/2025
60CDA02DOPAMINE HCL (ADRENERGIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/17/2025
61TCA37AMISULPRIDE
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/14/2025
56YCS99ANTIBIOTIC N.E.C.
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/16/2024
66NDA04RISPERIDONE (TRANQUILIZER (ANTI-PSYCHOTIC) - PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/22/2024
66NCY04RISPERIDONE (TRANQUILIZER (ANTI-PSYCHOTIC) - PART II)
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/8/2024
66VCB99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/8/2024
66VCB99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
Division of Southeast Imports (DSEI)
11/1/2023
66VIY99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/18/2023
61MAY99ANTI-CONVULSANT, N.E.C.
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/18/2023
61MAY99ANTI-CONVULSANT, N.E.C.
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/17/2023
66VCA99MISCELLANEOUS PATENT MEDICINES, ETC.
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/17/2023
66VCA99MISCELLANEOUS PATENT MEDICINES, ETC.
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/11/2023
61HCY99ANTI-BACTERIAL, N.E.C.
75UNAPPROVED
Division of Southeast Imports (DSEI)
9/1/2022
61NDB99ANTI-DEPRESSANT N.E.C.
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/28/2022
65QCY31CHLORZOXAZONE (RELAXANT)
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/28/2022
64LCY67CLOBETASOL PROPIONATE (GLUCOCORTICOID)
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/3/2021
65QDA31CHLORZOXAZONE (RELAXANT)
75UNAPPROVED
Division of Southeast Imports (DSEI)
8/26/2021
56CCA54CEFIXIME (CEPHALOSPORINS)
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/22/2021
61NDY99ANTI-DEPRESSANT N.E.C.
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/26/2021
63EDY13PROPRANOLOL HCL (CARDIAC DEPRESSANT)
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/26/2021
61NCY80VENLAFAXINE HYDROCHLORIDE (ANTI-DEPRESSANT)
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/14/2019
61LDA38CLOPIDOGREL BISULFATE (ANTI-COAGULANT)
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/27/2018
64XCY11ISOTRETINOIN (KERATOLYTIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/19/2017
61NCA83ESCITALOPRAM OXALATE
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/1/2016
64XDF11ISOTRETINOIN (KERATOLYTIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
2/15/2011
61BCA04BICALUTAMIDE (ANTI-ANDROGEN)
186INSANITARY
Detroit District Office (DET-DO)

Frequently Asked Questions

What is Intas Pharmaceuticals Limited's FDA import refusal history?

Intas Pharmaceuticals Limited (FEI: 3000978756) has 26 FDA import refusal record(s) in our database, spanning from 2/15/2011 to 3/31/2025.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Intas Pharmaceuticals Limited's FEI number is 3000978756.

What types of violations has Intas Pharmaceuticals Limited received?

Intas Pharmaceuticals Limited has been cited for 4 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about Intas Pharmaceuticals Limited come from?

All FDA import refusal data for Intas Pharmaceuticals Limited is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.